

Tony Panzarella, P.Stat.

Curriculum Vitae

📞 (647) 295 9548

📞 (416) 978 8979

✉️ tony.panzarella@utoronto.ca

Date Prepared

June 29, 2023

Education

1980–1984 **Honours BSc.**, *Faculty of Arts and Science, University of Toronto*, Toronto, Ontario
Double Major - Mathematics and Statistics

1984–1985 **MSc.**, *Department of Statistical Sciences, University of Toronto*, Toronto, Ontario
Applied Statistics

Employment History

1985–2017 **Biostatistician**, *Biostatistics Department, Princess Margaret Cancer Centre*, Toronto, ON

Provided experimental design and statistical analysis support in a collaborative setting.

Prepared and reviewed statistical sections for abstracts/manuscripts.

Generated reports detailing statistical design and analysis.

Provided general consults

Gave introductory biostatistics lectures to residents and fellows in the major oncology groups

1998–2017 **Manager**, *Biostatistics Department, Princess Margaret Cancer Centre*, Toronto, ON

Managed day-to-day operations of a biostatistics unit comprised of 10 biostatisticians and one SAS programmer

Allocated new study requests

Hired employees, monitored, and evaluated staff performance

Prepared annual budget and reviewed finances monthly

Oversaw cost recovery process

2018–present **MSc. Program Director**, *Division of Biostatistics, Dalla Lana School of Public Health*, Toronto, ON

Responsible for day-to-day operations overseeing a program of 30–50 students who are enrolled in one of three program options: course-only, course-only with an emphasis in artificial intelligence and data science, and thesis.

Chair of Biostatistics MSc. Admissions Committee; Member, Biostatistics Curriculum Committee; Provide supervision of divisional administrative assistant;

Academic Appointments

- 2003–2007 **Adjunct Lecturer**, *Public Health Sciences Department, Faculty of Medicine, University of Toronto, Toronto, ON*
Provided three lectures to master's level students in Public Health for course Community Health Appraisal Methods
Assisted with marking and the design of the final examination.
Supervised Lab Course (CHL5207Y) student in 2004-2005.
Provided invited talk "Guidelines for Reporting Study Results" to Lab Course students Oct. 13, 2005.
Guest lectures - Introduction to Biostatistics, Research Methods I course in Medical Radiation Sciences Program, March 6 and 13, 2006 and March 12, 2007.
Helped co-ordinate and conduct Lab Course (CHL5207Y) in 2006-2007.
- 2007–2017 **Assistant Professor, Status-Only**, *Public Health Sciences Department, Faculty of Medicine, University of Toronto, Toronto, ON*
Course Director and Instructor, CHL5207Y/5208Y
MSc. Admissions Committee member from 2008 to present
Co-organizer of Biostatistics Workshop in Cancer Research July 24-26, 2009
Tutorial leader for HAD5303H: Controlled Clinical Trials from 2009 to 2015
- 2018–present **Assistant Professor, Non-tenure Stream**, *Dalla Lana School of Public Health, Toronto, ON*
Sole Instructor, CHL5210H (Categorical Data Analysis);
Course Director and Lead Instructor, CHL5207Y/5208Y (Lab Course)
Guest lecturer CHL5004H (Introduction to Public Health) and MSC1010/1011H (Seminar Series in Translational Research)

Statistical Leadership

- 2019–2025 **President**, *Southern Ontario Regional Association, Statistical Society of Canada and Southern Ontario Chapter, American Statistical Association*
- 2022–2025 **Board Member**, *Regional Representative of Ontario, Board of Directors, Statistical Society of Canada*

Honours and Awards

- 2005 **Clinical Teacher Award**, *In Support of Radiation Medicine Program for contribution to the statistical education of staff radiation therapists, Princess Margaret Cancer Centre*
- 2010 **The Brain Tumor Foundation of Canada Award**, *For Excellence in Psychosocial Oncology at the International Psychosocial Oncology Society meeting in Quebec City, June 2010. K. Edelstein, B. J. Spiegler, S. Fung, T. Panzarella, D. C. Hodgson, D. J. Mabbott, N. Laperriere, U. Tabori, E. Bouffet, W. P. Mason. Long-term neurocognitive outcomes in adult survivors of childhood medulloblastoma*
- 2012 **Bush Award for Academic Excellence in Research by a Fellow (Chris Fosker)**, *"The Importance of Poor Performance Status in Personalizing Palliative Radiotherapy towards the End of Life" (Fosker C, Panzarella T. and Wong R.) presented at the U of T Annual Research Day May 2012.*

- 2016 **Paper of Year Award**, *Canadian Hematology Society Paper of the Year Award for "Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with hematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial" published in Lancet Oncology*
- 2019 **Community Outreach Award, Statistical Society of Canada**, *Awarded \$5,000.00 for proposal "For Today's Graduate, Just One Word: Statistics". This proposal called for a one-day event at the University of Toronto for STEM girls and their teachers from throughout Southern Ontario to introduce them to careers in statistics through the lens of successful women statisticians.*
- 2022 **Nominee - Award of Excellence**, *Ontario Ministry of Colleges and Universities, Every Day Hero Category.*
- 2023 **Public Health Sciences Award for Excellence in Teaching - Open Teaching Category**, *Dalla Lana School of Public Health , 2022–2023*

Professional Affiliations

- 1986–present **Society for Clinical Trials**
- 2008–present **Statistical Society of Canada**
- 2018–present **American Statistical Association**

Accreditation

- 2008–present **Professional Statistician (P.Stat.)**, *Statistical Society of Canada*

Student Supervision

- May–Dec 2021 **Biostatistics Training Initiative Internship Program**, *Ontario Institute for Cancer Research*, Statistical design and analysis issues analyzing a phase III randomized clinical trial for the prevention of chronic graft-versus-host disease in cancer patients who have received an allogeneic bone marrow transplant from an unrelated donor., Shing Yu Wong, University of Waterloo \$27000

Committee Membership

- 1998–2004 **Research Ethics Board (Oncology)**, *Princess Margaret Cancer Centre, Toronto, ON*
- 1998–2017 **Cancer Registry and Data Access Committee**, *Princess Margaret Cancer Centre, Toronto, ON*
- 2003–2006 **Clinical Research Unit Executive Committee**, *Princess Margaret Cancer Centre, Toronto, ON*
- 2009–2015 **Research Ethics Board**, *Ontario Cancer Research Ethics Board, Toronto, ON*
- 2018–present **Graduate Curriculum Committee**, *Dalla Lana School of Public Health, Toronto, ON*
- 2022–present **Appointments and Promotions Committee**, *Dalla Lana School of Public Health, Toronto, ON*

- 2018–present **MSc. Admissions Committee**, *Chair*, Division of Biostatistics, Dalla Lana School of Public Health
Toronto, ON
- 2018–present **Biostatistics Curriculum Committee**, *Division of Biostatistics*, Dalla Lana School of Public Health, Toronto, ON
- 2018–present **Member, Data and Safety Monitoring Board**, *Canadian Myeloma Research Group*
- 2021–present **Education Council and Student Awards**, *Dalla Lana School of Public Health*, Toronto, ON
- 2021–present **Member, Data and Safety Monitoring Board**, *Canadian Donation and Transplantation Research Program*
- 2022–present **Member, Data and Safety Monitoring Board**, *Allphase Clinical Research Inc.*

Grants

- NIH (NCI) **Transplantation of G-CSF Stimulated Marrow vs. Blood**, *PI: Kirk Schultz*, Collaborators: Stephen Couban, Tony Panzarella, Cindy Toze, Gerry Devins, \$2,225,000 US
2006–2011
- Terry Fox **Improved Assignment to Best Available Therapy for Myelodysplasia/Acute Myeloid Leukemia**, *PI: Stephen Couban*, Collaborators: Kirk Schultz, Tony Panzarella, Ronan Foley et al., \$1,200,000 CAN
Research Institute 2012
- CIHR **A Randomized Trial of Thymoglobulin to Prevent Chronic Graft versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation from Unrelated Donors**, *PI: Irwin Ronald Walker*, Collaborators: Jean Roy, Tony Panzarella, Ronan Foley, Kirk Schultz, Stephen Couban, Stephanie Lee, Paul Martin, Arlene Nugent, \$1,200,000 CAN
2009–2013
- Canadian **Pre-consultation Educational Group Intervention to Improve Shared Decision Making for Postmastectomy Breast Reconstruction**, *PI: Toni Zhong*, Collaborators: Nancy Baxter, Brett Beber, Terry Cheng, Jeffrey Hoch, Stefan Hofer, Wanrudee Isaranuwachai, Jennifer Jones, Kelly Metcalfe, Anne O'Neill, Tony Panzarella, Jennica Platt, \$352,785 CAN
Breast Cancer Foundation 2015–2018

Invited Talks

- Apr 2010 **Minimization and Statistics for CBMTG 0801. Pre-conference Workshop**, *12th Biennial CBMTG conference*, Vancouver, BC
- Apr 2010 **Statistical Issues in Transplant Trials**, *12th Biennial CBMTG conference*, Vancouver, BC
- Apr 2012 **Preventing Missing Outcome Data in Randomized Clinical Trials**, *CBMTG 0801 Data Coordinators Meeting - CBMTG 2012 Annual Meeting*
- May 2012 **Data Integrity – A Statistician's Perspective.**, *Clinical Trials Week*, Princess Margaret Cancer Centre, Toronto, ON

- Dec 2012 **Statistical Analysis of Quantitative Data**, *Advanced Practice Nurse Educator Research Seminar Series sponsored by University Health Network's Collaborative Academic Practice*, Toronto, ON
- Aug 2013 **An Introduction to Statistics in Clinical Trials for the Non-statistician**, *Celgene Canada*, Collingwood, ON
- Nov 2013 **Introduction to Research Methods**, *Michener Institute*, Toronto, ON
- Sep 2014 **The Role of Biostatistics in a School of Public Health**, *Dalla Lana School of Public Health*, Toronto, ON
- Mar 2016 **Statistics 101 – Design, Analysis and Reporting Concepts.**, *Integrity in Graduate Research Workshop*, University of Toronto, Toronto, ON
- Dec 2016 **The Misuse of Statistics is Unethical**, *University of Toronto Research Ethics Board Retreat*, University of Toronto, Toronto, ON
- Jun 2021 **Working in a Statistical Consulting Group for a University-Affiliated Teaching Hospital: Opportunities and Challenges**, *Statistical Society of Canada Annual Meeting*, Virtual

Published Book Chapters

- 2010 **Prognosis and Survival Prediction**, *Journal of Alternative Medicine Research*, Pang J; Panzarella T; Chow E. Vol. 2, Issue 3, 309-332
- 2014 **The value of a collaborating biostatistician**, *Research for the Radiation Therapist: From Question to Culture* C. Gillian, L Di Prospero, N Harnett, L Holden, editors. CRC Press, Panzarella T.

Conference Presentations

- 2009 **30th Annual Meeting of the Society For Clinical Trials - Pre-Conference Workshop on Global Harmonization of the Research Ethics Submission and Review process**, *Harmonizing the system of research ethics review involving humans in Canada*, Atlanta, GA
- 2011 **32nd Annual Meeting of the International Society for Clinical Biostatistics**, *Comparing the effect of an inaccurate control group event rate using fixed absolute and relative treatment differences when re-estimating a sample size for a randomized clinical trial with a dichotomous outcome.*, Ottawa, ON
- 2011 **32nd Annual Meeting of the Society of Clinical Trials**, *A Case for Using Absolute Treatment Differences when Designing a Clinical Trial with a Dichotomous Outcome.*, Vancouver, BC

Grant Panels

- Jun 2011 **Cancer Research Society**
- Jun 2012 **Cancer Research Society**
- Sep 2017 **Canadian Cancer Society**, *Quality of Life Competition*

Course Development

- 2003, 2004 **Applied Biostatistics**, *A 9-week course offered to clinical researchers seeking a better understanding of the importance of statistics in medical research*, University Health Network, Toronto, ON
- 2004, 2005 **Introduction to Biostatistics**, *A 4-session introduction featuring types of data, summarization of data, probability distributions, sampling distributions, hypothesis tests, p-values, and reporting results*, Radiation Therapy, Princess Margaret Cancer Centre, Toronto, ON
- 2021, 2022 **MSC1030H**, *Learning from Data - Introduction to Study Design and Statistical Analysis Methods*, Institute of Medical Sciences, Temerty Faculty of Medicine Toronto, ON

Professional Development - Selected Short Courses

- Mar 2005 **Longitudinal Analysis Including Multi-level Modeling**, *Georges Monette*, York University
- May 2010 **Applied Bayesian Analysis**, *Michael Escobar*, Andy Willan, University of Toronto
- May 2013 **Successful Data Mining in Practice**, *Richard De Veaux*, Williams College
- June 2018 **Network Meta-analysis**, *Christopher Schmid*, Brown University
- May 2019 **Regression Modeling Strategies**, *Frank Harrell*, Vanderbilt University
- May 2020 **Introduction to Machine Learning for Biomedical Data**, *Noah Simon*, University of Washington
- May 2022 **Regression Diagnostics**, *John Fox*, McMaster University
- May 2023 **Fundamentals of Causal Inference**, *Babette Brumback*, University of Florida

Leadership/Management Courses

- Jul 1999 **Leadership in Action**, *Joe Sherran*
- Jan–Jun 2002 **Cairncrest Leadership Coaching**, *Jake MacArthur*
- Jan 2003 **Coaching for High Performance**, *Peter Jensen*
- 2006–2007 **Rotman Leadership Development Program**, *University Of Toronto*

Statistical Software

- 1985–present **SAS**, *Base, Stat and Graph*, Courses: SAS Programming I, SAS Programming II, SAS Macros, Survival Analysis Using the Cox Proportional Hazards Model, Longitudinal Data Analysis with Discrete and Continuous Responses
- 2004–present **R**, *Base, ggplot2*, Courses: Introduction to R, York University

Publications (ordered alphabetically by first author)

- [1] O. Abe, R. Abe, K. Asaishi, K. Enomoto, T. Hattori, Y. Ino, K. Kikuchi, H. Koyama, K. Sawa, J. Uchino, et al., *Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences*

and 24,000 deaths among 75,000 women. part i, *Obstetrical and Gynecological Survey*, 47 (1992), pp. 405–407.

- [2] O. Abe, R. Abe, K. t. Enomoto, K. Kikuchi, H. Koyama, Y. Nomura, K. Sakai, K. Sugimachi, T. Tominaga, J. Uchino, et al., *Tamoxifen for early breast cancer: an overview of the randomised trials*, *The Lancet*, 351 (1998), pp. 1451–1467.
- [3] Y. Alayed, T. Craig, C. Catton, P. Warde, P. Chung, A. Bayley, T. Panzarella, and C. Menard, *Clinical impact of reducing planning target volume margins during radiation therapy for localized prostate cancer: Early outcomes of a 2-stage prospective trial*, *International Journal of Radiation Oncology, Biology, Physics*, 93 (2015), p. E249.
- [4] M. Ali, T. Schechter, T. Panzarella, D. Villa, J. Kuruvilla, V. Kukreti, R. Tsang, J. J. Doyle, and M. Crump, *Autologous stem cell transplantation for adolescents and young adults with relapsed and refractory hodgkin lymphoma*, *Blood*, 116 (2010), p. 2402.
- [5] G. Alshumrani, M. O'Malley, S. Ghai, U. Metser, J. Kachura, A. Finelli, K. Mattar, and T. Panzarella, *Small (4 cm) cortical renal tumors: characterization with multidetector ct*, *Abdominal imaging*, 35 (2010), pp. 488–493.
- [6] A. D. Altman, S. E. Ferguson, E. G. Atenafu, M. Köbel, J. N. McAlpine, T. Panzarella, S. Lau, L. T. Gien, B. Gilks, B. Clarke, et al., *Canadian high risk endometrial cancer (chrec) consortium: analyzing the clinical behavior of high risk endometrial cancers*, *Gynecologic oncology*, 139 (2015), pp. 268–274.
- [7] H. Atlas, F. Moustarah, M. Anvari, S. Wiebe, P. Graham, A. Vizhul, R. Seth, K. Croome, M.-A. Aarts, K. Sarkhosh, et al., *Canadian Journal of Surgery*, 53 (2010), pp. S51–S104.
- [8] J. Bartoszko, T. Panzarella, A. Lau, A. Schimmer, A. Schuh, M. Shanavas, K. Yee, and V. Gupta, *Effect of red blood cell transfusion dependence on the natural history of myeloproliferative neoplasm-associated myelofibrosis*, *Clinical Lymphoma Myeloma and Leukemia*, 15 (2015), pp. e151–e156.
- [9] J. Bartoszko, T. Panzarella, C. J. McNamara, A. Lau, A. D. Schimmer, A. C. Schuh, H. Sibai, D. Maze, K. W. Yee, R. Devlin, et al., *Distribution and impact of comorbidities on survival and leukemic transformation in myeloproliferative neoplasm-associated myelofibrosis: a retrospective cohort study*, *Clinical Lymphoma Myeloma and Leukemia*, 17 (2017), pp. 774–781.
- [10] J. Bartoszko, T. Panzarella, C. J. McNamara, A. Lau, A. D. Schimmer, A. C. Schuh, H. Sibai, K. W. Yee, M. D. Minden, R. Devlin, et al., *Distribution and impact of comorbidities on survival and leukemic transformation in myeloproliferative neoplasm (mpn)-associated myelofibrosis (mf)*, *Blood*, 128 (2016), p. 4264.
- [11] S. Baxi, P. Warde, J. Sweet, T. Panzarella, K. Shun, M. Gospodarowicz, M. Jewett, M. Moore, J. Sturgeon, and P. Chung, *Prevalence of pathological features in*

advanced seminoma: Implications for management of stage i disease., Journal of Clinical Oncology, 28 (2010), pp. e15018–e15018.

- [12] J. L. Bender, D. Feldman-Stewart, C. Tong, K. Lee, M. Brundage, H. Pai, J. Robinson, and T. Panzarella, *Health-related internet use among men with prostate cancer in canada: Cancer registry survey study*, Journal of Medical Internet Research, 21 (2019), p. e14241.
- [13] M. Q. Bernardini, L. T. Gien, C. Giede, V. Samouelian, H. Steed, S. E. Ferguson, B. Renkosinski, J. Abitbol, T. Warkus, T. Le, et al., *Goc2: A multi-centre prospective trial comparing open, laparoscopic and robotic surgical outcomes in women with endometrial cancer. part a: Perioperative outcomes*, Gynecologic Oncology, 145 (2017), p. 54.
- [14] M. Q. Bernardini, L. T. Gien, S. Lau, A. D. Altman, B. Gilks, S. E. Ferguson, M. Köbel, V. Samouëlian, M. Wesa, A. Cameron, et al., *Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (chrec)*, Gynecologic Oncology, 141 (2016), pp. 148–154.
- [15] A. Bezjak, J. Adam, R. Barton, T. Panzarella, N. Laperriere, C. Wong, W. Mason, C. Buckley, W. Levin, M. McLean, et al., *Symptom response after palliative radiotherapy for patients with brain metastases*, European Journal of Cancer, 38 (2002), pp. 487–496.
- [16] A. Bezjak, J. Adam, T. Panzarella, W. Levin, R. Barton, P. Kirkbride, M. McLean, W. Mason, C. S. Wong, and N. Laperriere, *Radiotherapy for brain metastases: defining palliative response*, Radiotherapy and Oncology, 61 (2001), pp. 71–76.
- [17] A. Bezjak, T. Panzarella, A. Fyles, J. Sturgeon, F. Pearson, D. Payne, and W. Simpson, *393 princess margaret hospital (pmh) experience with thymomas over a 28-year period*, Lung Cancer, (1997), p. 102.
- [18] H. Biran, R. Feld, U. Sagman, J. Rusthoven, F. Shepherd, W. Evans, R. Ginsberg, T. Panzarella, and A. Malkin, *Carcinoembryonic antigen, arginine vasopressin and calcitonin as markers of early small-cell lung cancer relapse*, Tumor Biology, 10 (1989), pp. 258–267.
- [19] D. Bloomfield, M. Krahn, T. Neogi, T. Panzarella, T. Smith, P. Warde, A. Willan, S. Ernst, M. Moore, A. Neville, et al., *Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a canadian randomized trial with palliative end points.*, Journal of clinical oncology, 16 (1998), pp. 2272–2279.
- [20] G. Bouchard-Fortier, T. Panzarella, B. Rosen, W. Chapman, and L. T. Gien, *Endometrioid carcinoma of the ovary: outcomes compared to serous carcinoma after 10 years of follow-up*, Journal of Obstetrics and Gynaecology Canada, 39 (2017), pp. 34–41.
- [21] C. Bredeson, C. Leger, S. Couban, D. Simpson, L. Huebsch, I. Walker, T. Shore, K. Howson-Jan, T. Panzarella, H. Messner, et al., *An evaluation of the donor*

experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting, *Biology of Blood and Marrow Transplantation*, 10 (2004), pp. 405–414.

- [22] J. Brierley, P. Catton, B. O'Sullivan, J. Irish, J. Sturgeon, and T. Panzarella, *2236 how accurately is the tnm stage recorded in a tertiary cancer center?*, *International Journal of Radiation Oncology, Biology, Physics*, 3 (1999), p. 399.
- [23] J. Brierley, R. Tsang, T. Panzarella, and N. Bana, *Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years*, *Clinical endocrinology*, 63 (2005), pp. 418–427.
- [24] J. Brierley, R. Tsang, T. Panzarella, and M. Gospodarowicz, *Improved survival and reduced local relapse following external beam radiotherapy in papillary thyroid cancer with microscopic residuum following surgical excision*, *International Journal of Radiation Oncology. Biology. Physics*, 39 (1997), pp. 310–310.
- [25] J. Brierley, R. Tsang, W. Simpson, M. Gospodarowicz, S. Sutcliffe, and T. Panzarella, *Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control*, *Thyroid*, 6 (1996), pp. 305–310.
- [26] J. Brierley, C. Wong, B. Cummings, P. Catton, J. Ringash, C. Catton, M. McLean, T. Keane, and T. Panzarella, *Squamous cell carcinoma of the oesophagus treated with radiation and 5-fluorouracil, with and without mitomycin c*, *Clinical Oncology*, 13 (2001), pp. 157–163.
- [27] J. D. Brierley, P. A. Catton, B. O'Sullivan, J. E. Dancey, A. J. Dowling, J. C. Irish, T. S. McGowan, J. F. Sturgeon, C. J. Swallow, G. B. Rodrigues, et al., *Accuracy of recorded tumor, node, and metastasis stage in a comprehensive cancer center*, *Journal of clinical oncology*, 20 (2002), pp. 413–419.
- [28] J. D. Brierley, T. Panzarella, R. W. Tsang, M. K. Gospodarowicz, and B. O'Sullivan, *A comparison of different staging systems predictability of patient outcome: thyroid carcinoma as an example*, *Cancer: Interdisciplinary International Journal of the American Cancer Society*, 79 (1997), pp. 2414–2423.
- [29] C. Catton, M. Gospodarowicz, J. Mui, T. Panzarella, M. Milosevic, M. McLean, P. Catton, and P. Warde, *Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer.*, *The Canadian Journal of Urology*, 9 (2002), pp. 1444–52.
- [30] C. Catton, M. Gospodarowicz, P. Warde, T. Panzarella, P. Catton, M. McLean, and M. Milosevic, *Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate*, *Radiotherapy and Oncology*, 59 (2001), pp. 51–60.
- [31] ———, *Response to wiecel and hinkelbein*, *Radiotherapy and Oncology*, 62 (2002), pp. 115–116.

- [32] C. Catton, B. O'Sullivan, R. Bell, B. Cummings, V. Fornasier, and T. Panzarella, *Aggressive fibromatosis: optimisation of local management with a retrospective failure analysis*, *Radiotherapy and Oncology*, 34 (1995), pp. 17–22.
- [33] E. Chow, M. Abdoell, T. Panzarella, K. Harris, A. Bezjak, P. Warde, and I. Tannock, *Predictive model for survival in patients with advanced cancer*, *J Clin Oncol*, 26 (2008), pp. 5863–5869.
- [34] ———, *Recursive partitioning analysis of prognostic factors for survival in patients with advanced cancer*, *International Journal of Radiation Oncology* Biology* Physics*, 73 (2009), pp. 1169–1176.
- [35] ———, *Validation of a predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic*, *International Journal of Radiation Oncology* Biology* Physics*, 73 (2009), pp. 280–287.
- [36] E. Chow, L. Davis, T. Panzarella, C. Hayter, E. Szumacher, A. Loblaw, R. Wong, and C. Danjoux, *Accuracy of survival prediction by palliative radiation oncologists*, *International Journal of Radiation Oncology* Biology* Physics*, 61 (2005), pp. 870–873.
- [37] E. Chow, K. Fung, T. Panzarella, A. Bezjak, C. Danjoux, and I. Tannock, *A predictive model for survival in metastatic cancer patients attending an outpatient palliative radiotherapy clinic*, *International Journal of Radiation Oncology* Biology* Physics*, 53 (2002), pp. 1291–1302.
- [38] E. Chow, T. Keane, D. Payne, M. Izard, and T. Panzarella, *Enhanced radiocurability of cervical lymph node metastases arising from nasopharyngeal carcinoma compared with nodal metastases from other head and neck squamous carcinomas*, *International Journal of Radiation Oncology. Biology. Physics*, 36 (1996), pp. 338–338.
- [39] E. Chow, A. Ling, L. Davis, T. Panzarella, and C. Danjoux, *Pain flare following external beam radiotherapy and meaningful change in pain scores in the treatment of bone metastases*, *Radiotherapy and oncology*, 75 (2005), pp. 64–69.
- [40] E. Chow, A. Loblaw, K. Harris, M. Doyle, P. Goh, H. Chiu, T. Panzarella, M. Tsao, E. A. Barnes, E. Sinclair, et al., *Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastases—a pilot study*, *Supportive care in cancer*, 15 (2007), pp. 643–647.
- [41] E. Chow, D. Payne, T. Keane, T. Panzarella, and M. A. Izard, *Enhanced control by radiotherapy of cervical lymph node metastases arising from nasopharyngeal carcinoma compared with nodal metastases from other head and neck squamous cell carcinomas*, *International Journal of Radiation Oncology* Biology* Physics*, 39 (1997), pp. 149–154.
- [42] P. Chung, G. Daugaard, S. Tyldesley, E. G. Atenafu, T. Panzarella, C. Kollmannsberger, and P. Warde, *Evaluation of a prognostic model for risk of relapse in stage i seminoma surveillance*, *Cancer medicine*, 4 (2015), pp. 155–160.

- [43] P. Chung, G. Daugaard, S. Tyldesley, T. Panzarella, C. Kollmannsberger, M. Gospodarowicz, and P. Warde, *Prognostic factors for relapse in stage i seminoma managed with surveillance: A validation study.*, Journal of Clinical Oncology, 28 (2010), pp. 4535–4535.
- [44] P. Chung, M. O'Malley, M. Jewett, T. Panzarella, D. Hogg, M. Moore, P. Bedard, L. Anson-Cartwright, B. Tew-George, M. Haider, et al., *Evaluation of low-dose ct scans for surveillance in stage i testicular cancer.*, Journal of Clinical Oncology, 29 (2011), pp. 4565–4565.
- [45] P. Chung, M. E. O'Malley, M. A. Jewett, P. L. Bedard, T. Panzarella, J. Sturgeon, M. J. Moore, R. Hamilton, A. R. Hansen, L. Anson-Cartwright, et al., *Detection of relapse by low-dose computed tomography during surveillance in stage i testicular germ cell tumours*, European urology oncology, 2 (2019), pp. 437–442.
- [46] P. Chung, C. Parker, T. Panzarella, M. Gospodarowicz, S. Jewett, M. Milosevic, C. Catton, A. Bayley, B. Tew-George, M. Moore, et al., *Surveillance in stage i testicular seminoma-risk of late relapse.*, The Canadian journal of urology, 9 (2002), pp. 1637–1640.
- [47] P. W. Chung, M. K. Gospodarowicz, T. Panzarella, M. A. Jewett, J. F. Sturgeon, B. Tew-George, A. J. Bayley, C. N. Catton, M. F. Milosevic, M. Moore, et al., *Stage ii testicular seminoma: patterns of recurrence and outcome of treatment*, European urology, 45 (2004), pp. 754–760.
- [48] P. W. Chung, P. R. Warde, T. Panzarella, A. J. Bayley, C. N. Catton, M. F. Milosevic, M. A. Jewett, J. F. Sturgeon, M. Moore, and M. K. Gospodarowicz, *Appropriate radiation volume for stage iia/b testicular seminoma*, International Journal of Radiation Oncology* Biology* Physics, 56 (2003), pp. 746–748.
- [49] R. Correa, S. Dunningan, T. Panzarella, S. Ferguson, K. Murphy, H. Mackay, and M. Bernardini, *Comparing overall survival in patients with epithelial ovarian, primary peritoneal or fallopian tube cancer who received chemotherapy alone versus neoadjuvant chemotherapy followed by delayed primary debulking*, Gynecologic Oncology, 120 (2011), p. S66.
- [50] S. Couban, M. Aljurf, S. Lachance, I. Walker, C. Toze, M. Rubinger, J. H. Lipton, S. J. Lee, J. Szer, R. Doocey, et al., *Filgrastim-stimulated bone marrow compared with filgrastim-mobilized peripheral blood in myeloablative sibling allografting for patients with hematologic malignancies: a randomized canadian blood and marrow transplant group study*, Biology of Blood and Marrow Transplantation, 22 (2016), pp. 1410–1415.
- [51] ———, *Erratum to" filgrastim-stimulated bone marrow compared with filgrastim-mobilized peripheral blood in myeloablative sibling allografting for patients with hematologic malignancies: A randomized canadian blood and marrow transplant group study"*[*biol blood marrow transplant* 2016; 22: 1410-1415], Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation, 23 (2017), p. 534.

- [52] S. Couban, M. Aljurf, S. Lachance, I. Walker, C. L. Toze, M. Rubinger, J. H. Lipton, S. J. Lee, J. Szer, R. Doocey, et al., *A canadian blood and marrow transplant group (cbmtg) randomised trial comparing g-csf mobilized peripheral blood versus g-csf stimulated bone marrow in recipients of sibling allografts for hematologic malignancies*, *Blood*, 122 (2013), p. 709.
- [53] S. Couban, D. R. Simpson, M. J. Barnett, C. Bredeson, L. Hubesch, K. Howson-Jan, T. B. Shore, I. R. Walker, P. Browett, H. A. Messner, et al., *A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies*, *Blood, The Journal of the American Society of Hematology*, 100 (2002), pp. 1525–1531.
- [54] S. Couban, A. Stewart, D. Loach, T. Panzarella, and J. Meharchand, *Autologous and allogeneic transplantation for multiple myeloma at a single centre*, *Bone marrow transplantation*, 19 (1997), pp. 783–789.
- [55] J. Crook, L. Grimard, J. Tsihlias, C. Morash, and T. Panzarella, *Interstitial brachytherapy for penile cancer: results for 30 patients*, *International Journal of Radiation Oncology, Biology, Physics*, 51 (2001), pp. 14–15.
- [56] J. Crook, L. Grimard, J. Tsihlias, C. Morash, and T. Panzarella, *Interstitial brachytherapy for penile cancer: an alternative to amputation*, *The Journal of urology*, 167 (2002), pp. 506–511.
- [57] J. Crook, M. Milosevic, P. Catton, I. Yeung, T. Haycocks, T. Tran, C. Catton, M. Mclean, T. Panzarella, and M. A. Haider, *Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy*, *Brachytherapy*, 1 (2002), pp. 66–73.
- [58] D. J. Dale, J. D. B. FHA, A. Easson, D. Gilmour, V. Gupta, M. Krzyzanowska, T. Panzarella, M. Thompson, and G. Zufelt, *Physician and registrar staging audit: How did they do?*, (2006).
- [59] P. Degendorfer, H. Cole, S. Sellmann, T. Panzarella, J. Brown, L. Tinker, M. Gospodarowicz, and A. Oza, *Development of clinical research process metrics and tracking improvement in quality assurance in clinical trials.*, *Journal of Clinical Oncology*, 29 (2011), pp. e16572–e16572.
- [60] C. Dickie, A. Parent, A. Griffin, T. Panzarella, P. Ferguson, J. Wunder, M. Sharpe, P. Chung, C. Catton, and B. O'Sullivan, *Examining the relationship between the location of local tumor recurrence and the radiotherapy treatment volume for extremity soft tissue sarcoma patients treated with limb salvage surgery and external beam radiotherapy*, *International Journal of Radiation Oncology, Biology, Physics*, 75 (2009), pp. S65–S66.
- [61] C. I. Dickie, A. Parent, A. Griffin, T. Craig, C. Catton, P. Chung, T. Panzarella, B. O'Sullivan, and M. Sharpe, *A device and procedure for immobilization of patients receiving limb-preserving radiotherapy for soft tissue sarcoma*, *Medical dosimetry*, 34 (2009), pp. 243–249.

- [62] C. I. Dickie, A. L. Parent, P. W. Chung, C. N. Catton, T. Craig, A. M. Griffin, T. Panzarella, P. C. Ferguson, J. S. Wunder, R. S. Bell, et al., *Measuring interfractional and intrafractional motion with cone beam computed tomography and an optical localization system for lower extremity soft tissue sarcoma patients treated with preoperative intensity-modulated radiation therapy*, International Journal of Radiation Oncology* Biology* Physics, 78 (2010), pp. 1437–1444.
- [63] M. Doherty, W. Chiu, S. Serra, P. Bedard, M. McNamara, A. Horgan, S. Kamel-Reid, H. Jiang, T. Panzarella, T. Yau, et al., *The use of genome sequencing to identify and mutation patterns in biliary tract cancers*, OncoTargets and Therapy, (2019).
- [64] M. K. Doherty, M. G. McNamara, P. Aneja, E. McInerney, S. Moignard, A. M. Horgan, H. Jiang, T. Panzarella, R. Jang, N. Dhani, et al., *Long term responders to palliative chemotherapy for advanced biliary tract cancer*, Journal of Gastrointestinal Oncology, 8 (2017), p. 352.
- [65] E. Dougherty, B. Pierce, C. Ma, T. Panzarella, G. Rodin, and C. Zimmermann, *Factors associated with work stress and professional satisfaction in oncology staff*, American Journal of Hospice and Palliative Medicine®, 26 (2009), pp. 105–111.
- [66] A. Dowling, T. Panzarella, D. Ernst, A. Neville, M. Moore, and I. Tannock, *A retrospective analysis of the relationship between changes in serum psa, palliative response and survival following systemic treatment in a canadian randomized trial for symptomatic hormone-refractory prostate cancer*, Annals of oncology, 12 (2001), pp. 773–778.
- [67] W. Duncan, C. Catton, P. Warde, M. Gospodarowicz, A. Munro, R. Lakier, J. Simm, and T. Panzarella, *The influence of transurethral resection of prostate on prognosis of patients with adenocarcinoma of the prostate treated by radical radiotherapy*, Radiotherapy and Oncology, 31 (1994), pp. 41–50.
- [68] S. Dunningan, T. Panzarella, S. Ferguson, K. Murphy, H. Mackay, and M. Bernardini, *Comparing overall survival in patients with epithelial ovarian, primary peritoneal or fallopian tube cancer who received chemotherapy alone versus neoadjuvant chemotherapy followed by delayed primary debulking*, Gynecologic Oncology, 120 (2011), p. 6.
- [69] K. Edelstein, B. Spiegler, S. Fung, T. Panzarella, D. Hodgson, D. Mabbott, N. Laperriere, U. Tabori, E. Bouffet, and W. Mason, *Long-term neurocognitive outcomes in adult survivors of childhood medulloblastoma.*, Journal of Clinical Oncology, 28 (2010), pp. 9554–9554.
- [70] K. Edelstein, B. J. Spiegler, S. Fung, T. Panzarella, D. J. Mabbott, N. Jewitt, N. M. D'Agostino, W. P. Mason, E. Bouffet, U. Tabori, et al., *Early aging in adult survivors of childhood medulloblastoma: long-term neurocognitive, functional, and physical outcomes*, Neuro-oncology, 13 (2011), pp. 536–545.
- [71] D. Ezeife, B. Melosky, R. Tudor, S. Lin, A. Lau, T. Panzarella, and N. Leighl, *Afatinib in advanced pretreated non-small-cell lung cancer—a canadian experience*, Current Oncology, 25 (2018), pp. 385–390.

- [72] F. Fekrmandi, T. Panzarella, R. Dinniwell, J. Helou, and W. Levin, *Predictive factors for persistent and late radiation complications in breast cancer survivors*, Clinical and Translational Oncology, 22 (2020), pp. 360–369.
- [73] S. E. Ferguson, W. H. Gotlieb, L. T. Gien, C. Giede, V. Samouelian, H. Steed, B. Renkosinski, J. Abitbol, T. Warkus, T. Le, et al., *Goc2: A multicenter prospective trial comparing open, laparoscopic and robotic surgical outcomes in women with endometrial cancer. part b: Patient-reported outcomes*, Gynecologic Oncology, 145 (2017), pp. 28–29.
- [74] S. E. Ferguson, T. Panzarella, S. Lau, L. T. Gien, V. Samouëlian, C. Giede, H. Steed, T. Le, B. Renkosinski, and M. Q. Bernardini, *Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer*, Gynecologic oncology, 149 (2018), pp. 476–483.
- [75] S. E. Ferguson, T. Panzarella, S. Lau, L. T. Gien, V. Samouelian, H. Steed, B. Renkosinski, S. Kosa, and M. Q. Bernardini, *A multi-centre prospective study comparing costs between robotics, laparoscopy and laparotomy in management of endometrial cancer*, Gynecologic Oncology, 154 (2019), pp. 222–223.
- [76] C. Fosker, T. Panzarella, S. Harris, A. Lau, M. Lau, C. Garraway, M. McLean, W. Levin, A. Bezjak, and R. Wong, *Tailoring palliative radiation therapy (rt) towards the end of life—the importance of ecog performance status*, International Journal of Radiation Oncology, Biology, Physics, 84 (2012), p. S51.
- [77] A. S. Gerrie, J. R. Mikhael, L. Cheng, H. Jiang, V. Kukreti, T. Panzarella, D. Reece, K. A. Stewart, Y. Trieu, S. Trudel, et al., *D (t) pace as salvage therapy for aggressive or refractory multiple myeloma*, British journal of haematology, 161 (2013), pp. 802–810.
- [78] P. J. Goodwin, T. Panzarella, and N. F. Boyd, *Weight gain in women with localized breast cancer—a descriptive study*, Breast cancer research and treatment, 11 (1988), pp. 59–66.
- [79] R. Goody, T. Panzarella, P. Lindsay, D. Paravasthu, A. Brade, L. Dawson, P. Chung, A. Bezjak, J. Brierley, J. Kim, et al., *Phase 2 study of normal tissue tolerance-adapted 5-fraction stereotactic body radiation therapy (sbrt) for extracranial oligometastases*, International Journal of Radiation Oncology, Biology, Physics, 96 (2016), pp. E118–E119.
- [80] D. Grabarz, T. Panzarella, A. Bezjak, M. Mclean, C. Elder, and R. K. Wong, *Quantifying interobserver variation in target definition in palliative radiotherapy*, International Journal of Radiation Oncology* Biology* Physics, 80 (2011), pp. 1498–1504.
- [81] V. Gupta, L. Li, T. Panzarella, J. Khan, A. Galal, J. Kuruvilla, J. Lipton, H. Messner, and S. Alibhai, *A longitudinal comparison of quality of life (qol) in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation*

- (allohct) using myeloablative (my) or reduced intensity conditioning (ric), *Biology of Blood and Marrow Transplantation*, 16 (2010), pp. S228–S229.
- [82] V. Gupta, T. Panzarella, L. Li, J. Khan, S. Alibhai, A. Galal, J. Kuruvilla, J. Lipton, and H. Messner, *A prospective comparison of outcomes and resource utilization in patients with myeloid malignancies undergoing allogeneic hematopoietic cell transplantation (allohct) using myeloablative or reduced intensity conditioning*, *Biology of Blood and Marrow Transplantation*, 16 (2010), p. S270.
 - [83] V. Gupta, T. Panzarella, L. Li, J. Khan, A. Sharma, J. H. Lipton, J. Kuruvilla, H. Messner, and S. M. Alibhai, *A prospective study comparing the outcomes and health-related quality of life in adult patients with myeloid malignancies undergoing allogeneic transplantation using myeloablative or reduced-intensity conditioning*, *Biology of Blood and Marrow Transplantation*, 18 (2012), pp. 113–124.
 - [84] L. A. Habib, K. H. Kuo, T. Panzarella, V. Gupta, and M. Trinkaus, *Management of polycythemia vera: a survey of canadian physician practice plans*, *Blood*, 130 (2017), p. 3382.
 - [85] ———, *Management of polycythemia vera: a survey of canadian physician practice patterns*, *Clinical Lymphoma Myeloma and Leukemia*, 19 (2019), pp. e37–e42.
 - [86] J. Higgins, A. Bezjak, A. Hope, T. Panzarella, W. Li, J. B. Cho, T. Craig, A. Brade, A. Sun, and J.-P. Bissonnette, *Effect of image-guidance frequency on geometric accuracy and setup margins in radiotherapy for locally advanced lung cancer*, *International Journal of Radiation Oncology* Biology* Physics*, 80 (2011), pp. 1330–1337.
 - [87] J. Higgins, A. Bezjak, A. Hope, T. Panzarella, W. Li, T. Craig, A. Brade, A. Sun, J. Cho, and J. Bissonnette, *15 impact of daily volumetric imaging in reducing set-up margins for lung cancer patients treated with conventionally fractionated radiotherapy*, *Radiotherapy and Oncology*, (2009), p. S5.
 - [88] J. Higgins, A. Bezjak, A. Hope, T. Panzarella, W. Li, T. Craig, A. Brade, A. Sun, J. Cho, and J. Bissonnette, *Impact of different image-guided protocols on geometric accuracy of radiotherapy for locally-advanced lung cancer*, *International Journal of Radiation Oncology, Biology, Physics*, 75 (2009), p. S98.
 - [89] J. Higgins, A. Bezjak, W. Li, T. Panzarella, and J. Bissonnette, *Is daily cone-beam ct image guidance required to correct setup error in conventionally fractionated lung radiotherapy?*, *International Journal of Radiation Oncology, Biology, Physics*, 72 (2008), pp. S441–S442.
 - [90] D. C. Hodgson, J. D. Brierley, R. W. Tsang, and T. Panzarella, *Prescribing 131iodine based on neck uptake produces effective thyroid ablation and reduced hospital stay*, *Radiotherapy and oncology*, 47 (1998), pp. 325–330.
 - [91] T. Hsu, P. C. Black, K. N. Chi, C. M. Canil, B. J. Eigl, G. Kulkarni, S. North, L. Wood, A. R. Zlotta, A. Lau, et al., *Treatment of muscle-invasive bladder cancer in canada: A survey of genitourinary medical oncologists and urologists*, *Canadian Urological Association Journal*, 8 (2014), p. 309.

- [92] T. Hsu, S. North, B. Eigl, K. Chi, C. Canil, L. Wood, A. Lau, T. Panzarella, and S. Sridhar, *The neoadjuvant management of bladder cancer in canada: A survey of genitourinary medical oncologists.*, Journal of Clinical Oncology, 29 (2011), pp. 285–285.
- [93] J. Hu, J. Sykes, T. Panzarella, A. Sharma, J. Kuruvilla, J. Lipton, J. Wright, H. Messner, and V. Gupta, *Attempts to optimizing the outcomes of allogeneic hematopoietic cell transplantation in older patients (60 years) with acute myeloid leukemia and myelodysplastic syndrome*, Biology of Blood and Marrow Transplantation, 17 (2011), pp. S311–S312.
- [94] D. Hwan, D. Kim, G. Al-Dawsari, H. Chang, T. Panzarella, V. Gupta, J. Kuruvilla, J. Lipton, and H. Messner, *Large granular lymphocytosis and its impact on long-term clinical outcomes following allo-sct*, Bone marrow transplantation, 48 (2013), pp. 1104–1111.
- [95] N. Isaac, T. Panzarella, A. Lau, C. Mayers, P. Kirkbride, I. F. Tannock, and K. A. Vallis, *Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: A well tolerated adjuvant regimen*, Cancer: Interdisciplinary International Journal of the American Cancer Society, 95 (2002), pp. 696–703.
- [96] S. Ivison, A. Kariminia, M. Levings, R. Broady, T. Panzarella, A. Albert-Green, M. Aljurf, H. Al Humaidan, R. Foley, G. Devins, et al., *Higher proportions of ifng-producing t cells, cd56bright nk cells and immature b cells in the lymphocytes of g-csf stimulated donor grafts are associated with less chronic gvhd after hsct: Results from the canadian bmt group 0601 randomized, phase iii trial*, Blood, 120 (2012), p. 1944.
- [97] M. D. Jain, R. D. Morin, A. Prica, V. Kukreti, R. Kridel, R. C. Laister, L. Meng, C. Rushton, M. Alcaide, R. S. Goswami, et al., *Obinutuzumab plus gemcitabine, dexamethasone and cisplatin (o-gdp) as salvage chemotherapy prior to autologous stem cell transplant in aggressive b cell lymphoma*, Blood, 132 (2018), p. 4610.
- [98] M. D. Jain, L. Mozessohn, L. M. Gerard, J. Ostro, M. Radwi, B. Routy, B. Gill, T. Panzarella, P. Anglin, M. C. Cheung, et al., *The ash practice improvement module in non-hodgkin lymphoma: assessing the feasibility, reliability and usefulness of a new quality improvement tool*, Blood, 124 (2014), p. 2651.
- [99] M. D. Jain, A. Prica, R. D. Morin, V. Kukreti, R. Kridel, R. C. Laister, L. Meng, C. Rushton, M. Alcaide, R. S. Goswami, et al., *Obinutuzumab plus gemcitabine, dexamethasone and cisplatin (o-gdp) as salvage chemotherapy prior to autologous stem cell transplant in aggressive b cell lymphoma*, Blood, 134 (2019), p. 2027.
- [100] D. Jenkin, J. Doyle, M. Berry, V. Blanchette, H. Chan, M. Doherty, M. Freedman, M. Greenberg, T. Panzarella, F. Saunders, et al., *Hodgkin's disease in children: Treatment with mopp and low-dose, extended field irradiation without laparotomy late results and toxicity*, Medical and pediatric oncology, 18 (1990), pp. 265–272.

- [101] M. A. s. Jewett, A. Finelli, I. Link, C. Morash, J. L. Chin, S. Pautler, R. Siemens, S. Tanguay, R. A. Rendon, M. E. Gleave, et al., *Active surveillance of small renal masses: a prospective multi-center canadian uro-oncology group trial*, The Journal of Urology, 181 (2009), pp. 320–320.
- [102] A. Kariminia, S. G. Holtan, S. Ivison, J. Rozmus, M.-J. Hebert, P. J. Martin, S. J. Lee, D. Wolff, P. Subrt, S. Abdossamadi, et al., *Heterogeneity of chronic graft-versus-host disease biomarkers: association with cxcl10 and cxcr3+ nk cells*, Blood, The Journal of the American Society of Hematology, 127 (2016), pp. 3082–3091.
- [103] A. Kariminia, S. Ivison, B. Ng, J. Rozmus, S. Sung, A. Varshney, M. Aljurf, S. Lachance, I. Walker, C. Toze, et al., *Cd56bright natural killer regulatory cells in filgrastim primed donor blood or marrow products regulate chronic graft-versus-host disease: the canadian blood and marrow transplant group randomized 0601 study results*, Haematologica, 102 (2017), p. 1936.
- [104] M. Kennah, N. Noroozi, E. Masih-Khan, T. Panzarella, D. E. Reece, S. Trudel, V. Kukreti, R. Tiedemann, and C. I. Chen, *Patient, disease and treatment characteristics of long-term survivors of multiple myeloma*, Blood, 124 (2014), p. 2019.
- [105] K. Kikuchi, H. Koyama, H. Masuda, Y. Nomura, D. Sakai, K. Sugimachi, T. Tom-inaga, J. Uchino, M. Yoshida, J. Haybittle, et al., *Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival*, The Lancet, 366 (2005), pp. 2087–2106.
- [106] P. Kirkbride, P. Warde, T. Panzarella, J. Aslanidis, M. McKenzie, and A. Sun, *A randomised trial comparing the efficacy of a single radiation fraction with fractionated radiation therapy in the palliation of skeletal metastases*, International Journal of Radiation Oncology. Biology. Physics, 48 (2000), pp. 185–185.
- [107] T. Kiss, T. Panzarella, H. Messner, J. Meharchand, V. Reddy, A. Schimmer, and J. Lipton, *Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-hodgkin's lymphoma*, Bone marrow transplantation, 31 (2003), pp. 73–78.
- [108] M. Köbel, E. G. Atenafu, P. F. Rambau, S. E. Ferguson, G. S. Nelson, T. Ho, T. Panzarella, J. N. McAlpine, C. B. Gilks, B. A. Clarke, et al., *Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A canadian high risk endometrial cancer consortium (chrec) study*, Gynecologic Oncology, 141 (2016), pp. 559–563.
- [109] S. D. Kosa, S. E. Ferguson, T. Panzarella, S. Lau, J. Abitbol, V. Samouëlian, C. Giede, H. Steed, B. Renkosinski, L. T. Gien, et al., *A prospective comparison of costs between robotics, laparoscopy, and laparotomy in endometrial cancer among women with class iii obesity or higher*, Journal of Surgical Oncology, 125 (2022), pp. 747–753.
- [110] K. H. Kuo, J. L. Callum, T. Panzarella, L. M. Jacks, J. Brandwein, M. Crump, J. E. Curtis, V. Gupta, J. H. Lipton, M. D. Minden, et al., *A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia*

presenting with hyperleucocytosis, British journal of haematology, 168 (2015), pp. 384–394.

- [111] J. Kuruvilla, P. Mollee, K. Song, Y. Zaretsky, T. Panzarella, J. McCrae, T. Nagy, M. Crump, and A. Keating, *A phase ii study of thalidomide and vinblastine for palliative patients with hodgkin's lymphoma*, Annals of Oncology, 16 (2005), pp. 198–198.
- [112] J. Kuruvilla, K. Song, P. Mollee, T. Panzarella, J. McCrae, T. Nagy, M. Crump, and A. Keating, *A phase ii study of thalidomide and vinblastine for palliative patients with hodgkin's lymphoma*, Hematology, 11 (2006), pp. 25–29.
- [113] J. Kwan, J. Croke, T. Panzarella, K. Ubhi, A. Fyles, A. Koch, R. Dinniwell, W. Levin, D. McCready, C. Chung, et al., *Personalizing post-treatment cancer care: a cross-sectional survey of the needs and preferences of well survivors of breast cancer*, Current Oncology, 26 (2019), pp. 138–146.
- [114] N. J. Laperriere, L. Cerezo, M. F. Milosevic, C. S. Wong, B. Patterson, and T. Panzarella, *Primary lymphoma of brain: results of management of a modern cohort with radiation therapy*, Radiotherapy and oncology, 43 (1997), pp. 247–252.
- [115] G. J. Laroye and T. Panzarella, *Two techniques for measuring invasion in solid tumors: Evaluated in a retrospective study of 73 cases of breast carcinoma with 10-year follow-up*, APMIS, 102 (1994), pp. 103–111.
- [116] L. W. Le and T. Panzarella, *Comparing two treatments of bone marrow transplant in the context of competing risks failure time*.
- [117] E. Lebel, M. Jain, A. Prica, V. Kukreti, R. Kridel, R. Laister, L. Meng, J. Delabie, J. Weiss, T. Panzarella, et al., *Prospective validation of recil response criteria: Results of obinutuzumab-gdp as salvage prior to autologous stem cell transplant in aggressive b cell lymphoma*, Hematological Oncology, 39 (2021).
- [118] G. Lee, R. Dinniwell, A. Fyles, T. Conrad, K. Han, W. Levin, F.-F. Liu, S. Lofgren, G. Devins, N. Emad, et al., *Radiation therapy patient experience survey of early-stage breast cancer women*, Journal of medical imaging and radiation sciences, 48 (2017), pp. S5–S6.
- [119] G. Lee, R. Dinniwell, A. Fyles, T. Conrad, K. Han, W. Levin, F.-F. Liu, S. Lofgren, A. Koch-Fitsialos, G. Devins, et al., *181: Patient experience survey of early-stage breast cancer patients undergoing whole breast radiotherapy*, Radiotherapy and Oncology, 1 (2016), pp. S66–S67.
- [120] G. Lee, R. Dinniwell, T. Fyles, T. Conrad, K. Han, W. Levin, F. Liu, S. Lofgren, A. Koch-Fitsialos, G. Devins, et al., *Patient experience survey of early-stage breast cancer patients undergoing whole-breast radiation therapy*, International Journal of Radiation Oncology, Biology, Physics, 96 (2016), p. E397.
- [121] G. Lee, N. Lalani, N. Emad, B. Gill, T. Panzarella, and C. Koch, *Prospective evaluation of normal tissue toxicity associated with breast boost in early-stage breast*

cancer radiation therapy, International Journal of Radiation Oncology, Biology, Physics, 93 (2015), pp. E27–E28.

- [122] E. Leung, P. Chung, T. Panzarella, M. Jewett, J. Sweet, M. O'Malley, M. Gospodarowicz, M. Moore, J. Sturgeon, and P. Warde, *Total treatment burden in stage i seminoma patients.*, Journal of Clinical Oncology, 28 (2010), pp. 4534–4534.
- [123] E. Leung, P. Warde, M. Jewett, T. Panzarella, M. O'Malley, J. Sweet, M. Moore, J. Sturgeon, M. Gospodarowicz, and P. Chung, *Treatment burden in stage i seminoma: a comparison of surveillance and adjuvant radiation therapy.*, BJU international, 112 (2013), pp. 1088–1095.
- [124] W. Levin, F. Fekrmandi, T. Panzarella, and R. Dinniwell, *Prognostic factors for persistent or late radiation side effects in breast cancer patients-clinical impact for survivors*, Cureus Journal of Medical Science, (2017).
- [125] S. Lheureux, Z. Lai, B. A. Dougherty, S. Runswick, D. R. Hodgson, K. M. Timms, J. S. Lanchbury, S. Kaye, C. Gourley, D. Bowtell, et al., *Long-term responders on olaparib maintenance in high-grade serous ovarian cancer: Clinical and molecular characterizationlong-term ovarian cancer responders to olaparib maintenance*, Clinical Cancer Research, 23 (2017), pp. 4086–4094.
- [126] J. H. Lipton, J. H. Lipton, P. Browett, H. A. Messner, H. A. Messner, T. Panzarella, K. H.-J. Howson-Jan, T. B. Shore, T. B. Shore, I. R. Walker, et al., *A randomized multicentre comparison of bone marrow and peripheral.*
- [127] M. Lishner, J. Slingerland, J. Barr, T. Panzarella, P. Degendorfer, and S. Sutcliffe, *Second malignant neoplasms in patients with non hodgkin's lymphoma*, Hematological oncology, 9 (1991), pp. 169–179.
- [128] M. Lishner, D. Zemlickis, P. Degendorfer, T. Panzarella, S. Sutcliffe, and G. Koren, *Maternal and foetal outcome following hodgkin's disease in pregnancy*, British journal of cancer, 65 (1992), pp. 114–117.
- [129] M. Lishner, D. Zemlickis, P. Degendorfer, T. PANZARELLA, S. SUTCLIFFE, and G. KOREN, *Maternal and fetal outcome following invasive cervical cancer in pregnancy*, Cancer in pregnancy. Cambridge University Press, Cambridge, (1996), pp. 120–130.
- [130] A. Loblaw, E. Chow, T. Panzarella, M. Tsao, E. Barnes, E. Sinclair, M. Farhadian, and C. Danjoux, *2568: Dexamethasone for the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone metastases*, International Journal of Radiation Oncology, Biology, Physics, 66 (2006), p. S525.
- [131] A. Loblaw, K. Harris, M. Doyle, P. Goh, H. Chiu, T. Panzarella, M. Tsao, E. Barnes, E. Sinclair, M. Farhadian, et al., *Dexamethasone for the prophylaxis of radiation-induced pain flare after palliative radiotherapy for bone metastasesâ a pilot study.*, Supportive Care in Cancer, 15 (2007).

- [132] D. A. Loblaw, J. S. Wu, P. Kirkbride, T. Panzarella, K. Smith, J. Aslanidis, and P. Warde, *Pain flare in patients with bone metastases after palliative radiotherapy—a nested randomized control trial*, *Supportive care in cancer*, 15 (2007), pp. 451–455.
- [133] M. Lock, E. Chow, V. Do, T. Panzarella, C. Danjoux, J. Lea, and A. Bezjak, *Prognostic factors in brain metastases: can we determine predictors of early death*, *International Journal of Radiation Oncology, Biology, Physics*, 51 (2001), pp. 255–256.
- [134] J. Martin, T. Panzarella, D. Zwahlen, P. Chung, and P. Warde, *Stage one seminoma: Evidence based guidelines for follow up*, *Journal of Clinical Oncology*, 24 (2006), pp. 4546–4546.
- [135] J. M. Martin, T. Panzarella, D. R. Zwahlen, P. Chung, and P. Warde, *Evidence-based guidelines for following stage 1 seminoma*, *Cancer*, 109 (2007), pp. 2248–2256.
- [136] K. Mattar, J. Azuero, R. Rendon, C. Morash, D. R. Siemens, J. L. Chin, A. Kapoor, A. Evans, N. E. Fleshner, A. Finelli, et al., *509: The natural history of small renal masses: A prospective multi-center canadian trial*, *The Journal of Urology*, 177 (2007), pp. 169–170.
- [137] K. Mattar, J. Basiuk, A. Finelli, N. Fleshner, S. Pautler, J. Chin, C. Morash, R. Siemens, R. Rendon, M. Gleave, et al., *Active surveillance of small renal masses: a prospective multi-centre canadian trial*, *European Urology Supplements*, 3 (2008), p. 309.
- [138] C. Mayers, T. Panzarella, and I. F. Tannock, *Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma*, *Cancer*, 91 (2001), pp. 2246–2257.
- [139] W. Mazrani, M. O'malley, P. Chung, P. Warde, D. Vesprini, and T. Panzarella, *Lymph node growth rate in testicular germ cell tumours: implications for computed tomography surveillance frequency*, *Clinical Oncology*, 23 (2011), pp. 333–338.
- [140] J. McCarthy, I. Tannock, P. Degendorfer, T. Panzarella, M. Furlan, and L. Siu, *A phase ii trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma*, *Oral oncology*, 38 (2002), pp. 686–690.
- [141] T. McGowan, B. Cummings, B. O'sullivan, C. Catton, N. Miller, and T. Panzarella, *An analysis of 78 breast sarcoma patients without distant metastases at presentation*, *International Journal of Radiation Oncology* Biology* Physics*, 46 (2000), pp. 383–390.
- [142] T. McGowanl, B. Cummings, N. Miller, and T. Panzarella, *An analysis of 78 breast sarcoma patients*, *International Journal of Radiation Oncology* Biology* Physics*, 24 (1992), p. 260.
- [143] M. Mclean, A. M. Akl, P. Wards, R. Bissett, T. Panzarella, and M. Gospodarowicz, *The results of primary radiation therapy in the management of squamous cell carcinoma of the penis*, *International Journal of Radiation Oncology* Biology* Physics*, 25 (1993), pp. 623–628.

- [144] M. McLean, E. Chow, B. O'Sullivan, A. Munro, P. M. Leung, D. A. Loblaw, and T. Panzarella, *Re-irradiation for locally recurrent nasopharyngeal carcinoma*, Radiotherapy and oncology, 48 (1998), pp. 209–211.
- [145] M. McLean, T. McGowan, C. Catton, P. Catton, and T. Panzarella, *The impact of prostatic manipulation upon serum psa in patients with adenocarcinoma of the prostate*, Clinical Oncology, 5 (1993), pp. 293–296.
- [146] M. McLean, T. Panzarella, and P. Warde, *Prostate-specific antigen changes during radiation therapy for adenocarcinoma of the prostate*, RADIATION ONCOLOGY INVESTIGATIONS CLINICAL AND BASIC RESEARCH, 4 (1996), pp. 98–99.
- [147] M. McLean, T. Panzarella, P. Warde, M. Gospodarowicz, W. Duncan, C. Catton, and R. Bissett, *Prostate specific antigen levels during radical radiation therapy and the prediction of outcome in localized carcinoma of the prostate*, Clinical Oncology, 9 (1997), pp. 226–233.
- [148] C. J. McNamara, T. Panzarella, J. A. Kennedy, A. Arruda, J. O. Claudio, G. Daher-Reyes, J. Ho, N. Siddiq, R. Devlin, H. Tsui, et al., *The mutational landscape of accelerated-and blast-phase myeloproliferative neoplasms impacts patient outcomes*, Blood advances, 2 (2018), pp. 2658–2671.
- [149] J. Meakin, J. Hayward, T. Panzarella, W. Allt, F. Beale, R. Bulbrook, R. Bush, R. Clark, P. Fitzpatrick, N. Hawkins, et al., *Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast*, Breast cancer research and treatment, 37 (1996), pp. 11–19.
- [150] R. Micallef, T. Panzarella, S. Scott, M. Lau, N. Sharma, A. Duggan, W. Levin, M. McLean, A. Bezjak, and R. Wong, *Palliative radiation for spinal metastases: Does the presence of soft tissue disease affect the choice of treatment dose and fractionation?*, International Journal of Radiation Oncology, Biology, Physics, 87 (2013), p. S566.
- [151] R. Micallef, T. Panzarella, S. Scott, M. Lau, N. Sharma, A. Duggan, W. Levin, M. McLean, A. Bezjak, R. Wong, et al., *Author disclosure: J. xue: None. t. lacouture: None. h. goldman: None. w. gault: None. y. chen: None. p. potrebko: None. r. croce: None. g. kubicek: None.*
- [152] T. Mikuls, J. Bernier, L. Wannesson, T. Panzarella, J. Mikhael, A. Keating, A. Surbone, M. Kagawa-Singer, C. Terret, L. Baider, et al., *European society for medical oncology volume 18| no. 4| april 2007.*
- [153] M. Milosevic, C. Angers, B. Liszewski, C. S. Drodge, E.-L. Marchand, J. P. Bissonnette, E. Brown, P. Dunscombe, J. Hunt, H. Jiang, et al., *The canadian national system for incident reporting in radiation treatment (nsir-rt) taxonomy*, Practical radiation oncology, 6 (2016), pp. 334–341.
- [154] M. Milosevic, R. Bristow, P. Chung, T. Panzarella, A. Toi, and R. Hill, *Prostate cancer hypoxia correlates with poor patient outcome following treatment with*

- radiotherapy, *International Journal of Radiation Oncology, Biology, Physics*, 60 (2004), pp. S236–S237.
- [155] M. Milosevic, R. Bristow, C. Ménard, T. Panzarella, P. Chung, A. Toi, P. Warde, C. Catton, and R. Hill, *Hypoxia is associated with early biochemical failure after radiotherapy in patients with prostate cancer*, *International Journal of Radiation Oncology, Biology, Physics*, 75 (2009), p. S105.
 - [156] M. Milosevic, P. Chung, T. Panzarella, A. Toi, R. Bristow, P. Warde, C. Catton, C. Ménard, M. Gospodarowicz, and R. Hill, *21: Androgen deprivation reduces hypoxia in human prostate cancer*, *International Journal of Radiation Oncology, Biology, Physics*, 66 (2006), p. S12.
 - [157] M. Milosevic, P. Chung, C. Parker, R. Bristow, A. Toi, T. Panzarella, P. Warde, C. Catton, C. Menard, A. Bayley, et al., *Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response*, *Cancer research*, 67 (2007), pp. 6022–6025.
 - [158] M. MILOSEVIC, P. CHUNG, C. PARKER, R. BRISTOW, A. TOI, T. PANZARELLA, P. WARDE, C. CATTON, C. MENARD, A. BAYLEY, et al., *Comment on: Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response*, *European urology*, 53 (2008), pp. 1085–1085.
 - [159] J.-P. Miron, J. Sheen, T. Panzarella, M. Hyde, F. Mansouri, L. Fox, H. Voetterl, V. D. Jodoin, P. Lespérance, C. Longpré-Poirier, et al., *The relationship between pre-treatment heart rate variability and response to low-frequency accelerated repetitive transcranial magnetic stimulation in major depression*, *Journal of Affective Disorders Reports*, 6 (2021), p. 100270.
 - [160] G. Mok, S. Baxi, T. Craig, J. Pertili, A. Lau, T. Panzarella, and C. Catton, *7010 poster discussion the impact of rectal distension present on planning scans on localized prostate cancer outcomes in the era of image-guided radiotherapy*, *European Journal of Cancer*, (2011), p. S487.
 - [161] J. Mui, C. Catton, P. Warde, M. Gospodarowicz, T. Panzarella, P. Catton, M. McLean, and M. Milosevic, *Radical irradiation of localized prostate cancer. prognosis and outcome based on clinical and biochemical assessment*, *International Journal of Radiation Oncology, Biology, Physics*, 1 (1998), p. 303.
 - [162] N. Naidoo, L. Zurawel-Balaura, A. Cheung, M. Lau, C. Garraway, T. Panzarella, M. Mclean, W. Levin, A. Bezjak, and R. Wong, *The role of specialized palliative radiotherapy (rt) programs: a decade of experience in a tertiary oncology center*, *International Journal of Radiation Oncology, Biology, Physics*, 81 (2011), p. S112.
 - [163] B. O'Sullivan, C. Catton, T. Panzarella, M. Johnston, R. Bell, and J. Wunder, *394 outcome in soft tissue sarcomas of the chest wall*, *Lung Cancer*, (1997), p. 102.
 - [164] K. Ottolino-Perry, E. Chamma, K. M. Blackmore, L. Lindvere-Teene, D. Starr, K. Tapang, C. F. Rosen, B. Pitcher, T. Panzarella, R. Linden, et al., *Improved*

detection of clinically relevant wound bacteria using autofluorescence image-guided sampling in diabetic foot ulcers, International wound journal, 14 (2017), pp. 833–841.

- [165] K. Ottolino-Perry, P. Medeiros, K. Blackmore, E. Chamma, I. Kulbatski, T. Panzarella, C. Rosen, S. Done, A. Easson, W. Leong, et al., *Handheld fluorescence imaging device for real-time intraoperative margin assessment of breast cancer: Ala-induced fluorescence for the detection of breast tumours*, The Breast, 1 (2017), p. S120.
- [166] K. Ottolino-Perry, A. Shahid, S. DeLuca, V. Son, M. Sukhram, F. Meng, Z. A. Liu, S. Rasic, N. T. Anantha, S. C. Wang, et al., *Intraoperative fluorescence imaging with aminolevulinic acid detects grossly occult breast cancer: a phase ii randomized controlled trial*, Breast Cancer Research, 23 (2021), pp. 1–20.
- [167] M. E. O'Malley, P. Chung, M. Haider, H.-J. Jang, K. Jhaveri, K. Khalili, T. Panzarella, and P. Warde, *Comparison of low dose with standard dose abdominal/pelvic multidetector ct in patients with stage 1 testicular cancer under surveillance*, European radiology, 20 (2010), pp. 1624–1630.
- [168] B. O'Sullivan, R. Bell, A. Davis, I. Quirt, C. Catton, J. Wunder, R. Kandel, B. Cummings, V. Formasier, M. Blackstein, et al., *The impact of an aggressive local control policy and of adjuvant chemotherapy in primary presentation extremity adult soft-tissue sarcoma in sequential cohorts over 20 years at the princess margaret hospital*, International Journal of Radiation Oncology, Biology, Physics, 3 (2000), p. 215.
- [169] M. Pablo, T. Panzarella, L. Dawson, A. Bezjak, P. Lindsay, P. Chung, A. Hope, M. Giuliani, C. Koch, B. Cummings, et al., *Prospective longitudinal assessment of quality of life and symptoms in patients with oligometastatic cancer treated with stereotactic body radiation therapy: Analysis of a phase 2 trial*, International Journal of Radiation Oncology, Biology, Physics, 99 (2017), pp. E542–E543.
- [170] T. PANZARELLA, M. lishner, d. zemlickis, p. degendorfer, t. panzarella, sb sutcliffe and g. koren, CANCER IN PREGNANCY: MATERNAL AND FETAL RISKS, p. 120.
- [171] T. Panzarella, *Statistical design and analysis issues analyzing a phase iii randomized clinical trial for the prevention of chronic graft-versus-host disease in cancer patients who have received an allogeneic bone marrow transplant from an unrelated donor background: ■ allogeneic bone marrow transplantation cures a wide range of hematological disorders; however*, 40.
- [172] ———, *P90 the problem with a heuristic approach to sample size estimation for time-to-failure endpoints involving three or more treatment groups*, Controlled Clinical Trials, 3 (1997), pp. S166–S167.
- [173] T. Panzarella, A. J. Dowling, and I. F. Tannock, *Analysis of survival by palliative response in patients with symptomatic hormone refractory prostate cancer*, Controlled Clinical Trials, 19 (1998), p. S77.

- [174] T. Panzarella, P. Kirkbride, and P. Warde, *P58 intention to treat analysis and the need for supplemental approaches for some trial designs*, *Controlled Clinical Trials*, 2 (1996), pp. S127–S128.
- [175] T. Panzarella and J. W. Meakin, *P34 applying cause-specific failure endpoint analysis strategies*, *Controlled Clinical Trials*, 3 (1995), p. 91S.
- [176] T. Panzarella, D. Villa, and J. Kuruvilla, *Reply to cs tam et al.*, *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 31 (2013), pp. 3167–3168.
- [177] T. Panzarella, P. Warde, C. Catton, C. Menard, A. Bayley, M. Gospodarowicz, and R. Hill, *Androgen withdrawal in patients reduces prostate cancer hypoxia: Implications for disease progression and radiation response*.
- [178] C. Parker, M. Milosevic, T. Panzarella, D. Banerjee, M. Jewett, C. Catton, B. Tew-George, M. Gospodarowicz, and P. Warde, *The prognostic significance of the tumour infiltrating lymphocyte count in stage i testicular seminoma managed by surveillance*, *European Journal of Cancer*, 38 (2002), pp. 2014–2019.
- [179] C. Parker, M. Milosevic, A. Toi, J. Sweet, T. Panzarella, R. Bristow, C. Catton, P. Catton, J. Crook, M. Gospodarowicz, et al., *Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer*, *International Journal of Radiation Oncology* Biology* Physics*, 58 (2004), pp. 750–757.
- [180] C. Parker, M. Milosevic, A. Toi, J. Sweet, T. Panzarella, A. Syed, R. Bristow, C. Catton, R. Hill, and P. Warde, *A polarographic electrode study of tumor oxygenation in localized prostate cancer*, *International Journal of Radiation Oncology, Biology, Physics*, 51 (2001), pp. 78–79.
- [181] C. Parker, P. Warde, A. Norman, T. Panzarella, C. Catton, A. Horwich, R. Huddart, and D. Dearnaley, *The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy±neoadjuvant androgen deprivation*, *International Journal of Radiation Oncology* Biology* Physics*, 58 (2004), pp. 53–58.
- [182] B. Patterson, J. Freedman, V. Blanchette, G. Sher, P. Pinkerton, B. Hannach, J. Meharchand, W. Lau, N. Boyce, E. Pinchfsky, et al., *Effect of premedication guidelines and leukoreduction on the rate of febrile nonhaemolytic platelet transfusion reactions.*, *Transfusion medicine (Oxford, England)*, 10 (2000), pp. 199–206.
- [183] B. Pierce, E. Dougherty, T. Panzarella, L. W. Le, G. Rodin, and C. Zimmermann, *Staff stress, work satisfaction, and death attitudes on an oncology palliative care unit, and on a medical and radiation oncology inpatient unit*, *Journal of Palliative Care*, 23 (2007), pp. 32–39.
- [184] J. Ponichtera, P. M. Schuffenegger, P. Lindsay, T. Panzarella, L. Dawson, A. Bezjak, A. Brade, P. Chung, J. Kim, A. Hope, et al., *Pv-0473 dosimetry, safety, efficacy and qol in a study of 5-fraction sbrt for oligometastatic (om) cancers*, *Radiotherapy and Oncology*, 127 (2018), p. S243.

- [185] J. Ponichtera, P. M. Schuffenegger, P. Lindsay, T. Panzarella, L. Dawson, A. Bezjak, A. Brade, P. Chung, J. Kim, A. Hope, et al., *Reasons for screen failure among patients identified as candidates for a phase 2 study of 5-fraction stereotactic body radiation therapy (sbrt) for oligometastatic cancer*, International Journal of Radiation Oncology, Biology, Physics, 102 (2018), p. e421.
- [186] M. A. Rafferty, D. P. Goldstein, L. Rotstein, S. L. Asa, T. Panzarella, P. Gullane, R. W. Gilbert, D. H. Brown, and J. C. Irish, *Completion thyroidectomy versus total thyroidectomy: is there a difference in complication rates? an analysis of 350 patients*, Journal of the American College of Surgeons, 205 (2007), pp. 602–607.
- [187] S. Randall Armel, J. McCuaig, A. Finch, R. Demsky, T. Panzarella, J. Murphy, and B. Rosen, *The effectiveness of family history questionnaires in cancer genetic counseling*, Journal of genetic counseling, 18 (2009), pp. 366–378.
- [188] R. A. Rendon, N. Stanietzky, T. Panzarella, M. Robinette, L. H. Klotz, W. Thurston, and M. A. Jewett, *The natural history of small renal masses*, The Journal of urology, 164 (2000), pp. 1143–1147.
- [189] P. O. Richard, S. M. Alibhai, T. Panzarella, L. Klotz, M. Komisarenko, N. E. Fleshner, D. Urbach, and A. Finelli, *The uptake of active surveillance for the management of prostate cancer: A population-based analysis*, Canadian Urological Association Journal, 10 (2016), p. 333.
- [190] J. Roy, T. Panzarella, S. Couban, F. Couture, G. M. Devins, M. Elemary, S. R. Foley, G. Gallagher, J. Kuruvilla, S. J. Lee, et al., *Less chronic graft-versus-host disease, immunosuppressive therapy and better survival after anti-thymocyte globulin in unrelated donor stem cell transplant recipients: Longer follow-up of a multicentre cell therapy transplant canada randomized trial*, Blood, 134 (2019), p. 875.
- [191] G. Salmasi, M. Li, V. Sivabalasundaram, T. Panzarella, R. Tsang, V. Kukreti, M. Crump, and J. Kuruvilla, *Incidence of pneumonitis in patients with non-hodgkin lymphoma receiving chemoimmunotherapy with rituximab*, Leukemia & Lymphoma, 56 (2015), pp. 1659–1664.
- [192] L. R. Shier, K. R. Schultz, S. Imren, J. Regan, A. Issekutz, I. Sadek, A. Gilman, Z. Luo, T. Panzarella, C. J. Eaves, et al., *Differential effects of granulocyte colony-stimulating factor on marrow-and blood-derived hematopoietic and immune cell populations in healthy human donors*, Biology of Blood and Marrow Transplantation, 10 (2004), pp. 624–634.
- [193] M. Sia, J. Brierley, R. Tsang, and T. Panzarella, *186 differentiated carcinoma of the thyroid with extra-thyroidal extension: Analysis of prognostic factors*, Radiotherapy and Oncology, (2005), p. S55.
- [194] M. Sia, J. Brierley, R. Tsang, and T. Panzarella, *Differentiated thyroid carcinoma: Analysis of extra-thyroidal extension and residual disease*, International Journal of Radiation Oncology, Biology, Physics, 63 (2005), p. S351.

- [195] M. A. Sia, R. W. Tsang, T. Panzarella, and J. D. Brierley, *Differentiated thyroid cancer with extrathyroidal extension: prognosis and the role of external beam radiotherapy*, Journal of thyroid research, 2010 (2010).
- [196] J. J. Silva, R. W. Tsang, T. Panzarella, W. Levin, and W. Wells, *Radiation therapy for epithelial skin cancer of the pinna*, International Journal of Radiation Oncology, Biology, Physics, 1 (1998), p. 330.
- [197] ———, *Results of radiotherapy for epithelial skin cancer of the pinna: the princess margaret hospital experience, 1982–1993*, International Journal of Radiation Oncology* Biology* Physics, 47 (2000), pp. 451–459.
- [198] W. Simpson, S. McKinney, J. Carruthers, M. Gospodarowicz, S. Sutcliffe, and T. Panzarella, *Papillary and follicular thyroid cancer: prognostic factors in 1,578 patients*, The American journal of medicine, 83 (1987), pp. 479–488.
- [199] W. Simpson, T. Panzarella, J. Carruthers, M. Gospodarowicz, and S. Sutcliffe, *Papillary and follicular thyroid cancer: impact of treatment in 1578 patients*, International Journal of Radiation Oncology* Biology* Physics, 14 (1988), pp. 1063–1075.
- [200] J. Spiegel, C. J. McNamara, A. Arruda, T. Panzarella, J. A. Kennedy, T. L. Stockley, M. Sukhai, M. Thomas, J. Bartoszko, J. M. Ho, et al., *Impact of genomic alterations on outcomes in myelofibrosis patients undergoing jak1/2 inhibitor therapy*, Blood, 128 (2016), p. 4263.
- [201] J. Y. Spiegel, C. McNamara, J. A. Kennedy, T. Panzarella, A. Arruda, T. Stockley, M. Sukhai, M. Thomas, J. Bartoszko, J. Ho, et al., *Impact of genomic alterations on outcomes in myelofibrosis patients undergoing jak1/2 inhibitor therapy*, Blood advances, 1 (2017), pp. 1729–1738.
- [202] C. Suen, J. Wong, K. Warsame, Y. Subramani, T. Panzarella, R. Waseem, D. Auckley, R. Chaudhry, S. Islam, and F. Chung, *Perioperative adherence to continuous positive airway pressure and its effect on postoperative nocturnal hypoxemia in obstructive sleep apnea patients: a prospective cohort study*, BMC anesthesiology, 21 (2021), p. 142.
- [203] I. Tannock, M. Gospodarowicz, W. Meakin, T. Panzarella, L. Stewart, and W. Rider, *Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response.*, Journal of Clinical Oncology, 7 (1989), pp. 590–597.
- [204] I. Tannock, D. Payne, B. Cummings, K. Hewitt, and T. Panzarella, *Sequential chemotherapy and radiation for nasopharyngeal cancer: absence of long-term benefit despite a high rate of tumor response to chemotherapy.*, Journal of clinical oncology, 5 (1987), pp. 629–634.
- [205] C. Timon, I. Dardick, T. Panzarella, J. Thomas, G. Ellis, and P. Gullane, *Clinicopathological predictors of recurrence for acinic cell carcinoma*, Clinical Otolaryngology & Allied Sciences, 20 (1995), pp. 396–401.

- [206] C. I. Timon, I. Dardick, T. Panzarella, B. Patterson, M. J. Thomas, G. L. Ellis, and P. J. Gullane, *Acinic cell carcinoma of salivary glands: prognostic relevance of dna flow cytometry and nucleolar organizer regions*, Archives of Otolaryngology–Head & Neck Surgery, 120 (1994), pp. 727–733.
- [207] L. Tinker, T. Panzarella, S. Sellmann, J. Brown, S. Webster, H. Cole, B. Fitzgerald, and P. Degendorfer, *Improving quality assurance in clinical trials (ct) through standardization: A review of source documentation practices at a large canadian cancer center.*, Journal of Clinical Oncology, 29 (2011), pp. e16577–e16577.
- [208] S. Tolan, D. Vesprini, M. A. Jewett, P. R. Warde, M. O'Malley, T. Panzarella, J. F. Sturgeon, M. Moore, B. Tew-George, M. K. Gospodarowicz, et al., *No role for routine chest radiography in stage i seminoma surveillance*, European urology, 57 (2010), pp. 474–479.
- [209] R. Tsang, J. Brierley, T. Panzarella, M. Gospodarowicz, S. Sutcliffe, and W. Simpson, *Role of radiation therapy in clinical hormonally-active pituitary adenomas*, Radiotherapy and oncology, 41 (1996), pp. 45–53.
- [210] R. Tsang, J. Brierley, W. J. Simpson, and T. Panzarella, *Radiotherapy for non-functional pituitary adenomas: Treatment results and prognostic factors*, International Journal of Radiation Oncology* Biology* Physics, 27 (1993), pp. 204–205.
- [211] R. Tsang, N. Laperriere, W. Simpson, J. Brierley, T. Panzarella, and H. Smyth, *Glioma arising after radiation therapy for pituitary adenoma. a report of four patients and estimation of risk*, Cancer, 72 (1993), pp. 2227–2233.
- [212] R. W. Tsang, J. D. Brierley, T. Panzarella, M. K. Gospodarowicz, S. B. Sutcliffe, and W. J. Simpson, *Radiation therapy for pituitary adenoma: treatment outcome and prognostic factors*, International Journal of Radiation Oncology* Biology* Physics, 30 (1994), pp. 557–565.
- [213] R. W. Tsang, J. D. Brierley, W. J. Simpson, T. Panzarella, M. K. Gospodarowicz, and S. B. Sutcliffe, *The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma*, Cancer: Interdisciplinary International Journal of the American Cancer Society, 82 (1998), pp. 375–388.
- [214] R. W. Tsang, M. K. Gospodarowicz, S. B. Sutcliffe, J. F. Sturgeon, T. Panzarella, B. J. Patterson, and T. P. M. H. L. Group, *Non-hodgkin's lymphoma of the thyroid gland: Prognostic factors and treatment outcome*, International Journal of Radiation Oncology* Biology* Physics, 27 (1993), pp. 599–604.
- [215] M. N. Tsao, R. W. Tsang, F.-F. Liu, T. Panzarella, and L. Rotstein, *Radiotherapy management for squamous cell carcinoma of the nasal skin: the princess margaret hospital experience*, International Journal of Radiation Oncology* Biology* Physics, 52 (2002), pp. 973–979.
- [216] D. Tsoref, T. Panzarella, and A. Oza, *Aspirin in prevention of ovarian cancer: are we at the tipping point?*, JNCI: Journal of the National Cancer Institute, 106 (2014).

- [217] D. Vesprini, P. Chung, S. Tolan, M. Gospodarowicz, M. Jewett, M. O'Malley, J. Sweet, M. Moore, T. Panzarella, J. Sturgeon, et al., *Utility of serum tumor markers during surveillance for stage i seminoma*, *Cancer*, 118 (2012), pp. 5245–5250.
- [218] D. Villa, M. Crump, A. Keating, T. Panzarella, B. Feng, and J. Kuruvilla, *Outcome of patients with transformed indolent non-hodgkin lymphoma referred for autologous stem-cell transplantation*, *Annals of oncology*, 24 (2013), pp. 1603–1609.
- [219] D. Villa, M. Crump, T. Panzarella, K. J. Savage, C. L. Toze, D. A. Stewart, D. A. MacDonald, R. Buckstein, C. Lee, M. Alzahrani, et al., *Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the canadian blood and marrow transplant group*, *J Clin Oncol*, 31 (2013), pp. 1164–1171.
- [220] D. Villa, A. George, J. F. Seymour, C. L. Toze, M. Crump, C. Lee, R. Buckstein, D. A. Stewart, D. MacDonald, R. Foley, et al., *Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma*, *Biology of Blood and Marrow Transplantation*, 20 (2014), pp. 1813–1818.
- [221] A. Viswabandya, T. Panzarella, D. D. H. Kim, V. Gupta, J. H. Lipton, H. A. Messner, and J. Kuruvilla, *Allogeneic stem cell transplantation is associated with long term disease control in chemo sensitive follicular lymphoma patients*, *Blood*, 118 (2011), p. 2024.
- [222] A. Volpe, T. Panzarella, R. A. Rendon, M. A. Haider, F. I. Kondylis, and M. A. Jewett, *The natural history of incidentally detected small renal masses*, *Cancer*, 100 (2004), pp. 738–745.
- [223] I. Walker, T. Panzarella, and S. Couban, *Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial (vol 17, pg 164, 2016)*, *LANCET ONCOLOGY*, 19 (2018), pp. E581–E581.
- [224] ———, *Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial (vol 7, pg e100, 2020)*, *LANCET HAEMATOLOGY*, 7 (2020), pp. E191–E191.
- [225] I. Walker, T. Panzarella, S. Couban, F. Couture, G. Devins, M. Elemary, G. Gallagher, H. Kerr, J. Kuruvilla, S. Lee, et al., *Anti-thymocyte globulin for patients undergoing hematopoietic cell transplantation from unrelated donors: A randomized, controlled, open-label, phase 3, multicentre trial from cell therapy transplant canada*, (2019).
- [226] I. Walker, T. Panzarella, S. Couban, F. Couture, G. Devins, M. Elemary, G. Gallagher, H. Kerr, J. Kuruvilla, S. J. Lee, et al., *Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies*

undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial, The Lancet Oncology, 17 (2016), pp. 164–173.

- [227] I. Walker, K. R. Schultz, C. L. Toze, H. M. Kerr, J. Moore, D. Szwajcer, S. R. Foley, J. Kuruvilla, T. Panzarella, F. Couture, et al., *Thymoglobulin decreases the need for immunosuppression at 12 months after myeloablative and nonmyeloablative unrelated donor transplantation: Cbmtg 0801, a randomized, controlled trial*, Blood, 124 (2014), p. 38.
- [228] L. Wannesson, T. Panzarella, J. Mikhael, and A. Keating, *Feasibility and safety of autotransplants with noncryopreserved marrow or peripheral blood stem cells: a systematic review*, Annals of Oncology, 18 (2007), pp. 623–632.
- [229] P. Warde, P. Chung, M. Jewett, T. Panzarella, M. Giuliani, B. Tew-George, A. Bayley, M. Milosevic, C. Catton, J. Sturgeon, et al., *Surveillance should be the standard approach in patients with stage i seminoma*, International Journal of Radiation Oncology, Biology, Physics, 63 (2005), p. S20.
- [230] P. Warde, P. Chung, J. Sturgeon, T. Panzarella, M. Giuliani, B. Tew-George, M. Jewett, A. Bayley, M. Moore, C. Catton, et al., *Should surveillance be considered the standard of care in stage i seminoma?*, Journal of Clinical Oncology, 23 (2005), pp. 4520–4520.
- [231] P. Warde, M. Gospodarowicz, D. Banerjee, T. Panzarella, L. Sugar, C. Catton, J. Sturgeon, M. Moore, and M. Jewett, *Prognostic factors for relapse in stage i testicular seminoma treated with surveillance*, The Journal of urology, 157 (1997), pp. 1705–1710.
- [232] P. Warde, M. Gospodarowicz, T. Panzarella, D. Banarjee, L. Sugar, C. Catton, J. Sturgeon, M. Moore, and M. Jewett, *Prognostic factors in stage i seminoma managed by surveillance.*, International Journal of Radiation Oncology. Biology. Physics, 32 (1995), pp. 165–165.
- [233] P. Warde, M. Gospodarowicz, T. Panzarella, C. Catton, J. Sturgeon, M. Moore, P. Goodman, and M. Jewett, *Stage i testicular seminoma: results of adjuvant irradiation and surveillance.*, Journal of clinical Oncology, 13 (1995), pp. 2255–2262.
- [234] P. Warde, M. Gospodarowicz, T. Panzarella, C. Catton, J. Sturgeon, M. Moore, and M. Jewett, *Management of stage ii seminoma.*, Journal of clinical oncology, 16 (1998), pp. 290–294.
- [235] P. Warde, M. Gospodarowicz, T. Panzarella, E. Chow, T. Murphy, C. Catton, J. Sturgeon, M. Moore, M. Milosevic, and M. Jewett, *Long term outcome and cost in the management of stage i testicular seminoma.*, The Canadian Journal of Urology, 7 (2000), pp. 967–72.
- [236] P. Warde, M. Gospodarowicz, T. Panzarella, M. Giuliani, E. Tew-George, M. Milosevic, A. Bayley, C. Catton, J. Sturgeon, M. Moore, et al., *719: Outcome in stage i*

seminoma managed by radiation therapy and surveillance, The Journal of Urology, 173 (2005), pp. 196–196.

- [237] P. Warde, M. Gospodarowicz, T. Panzarella, T. Murphy, C. Catton, J. Sturgeon, M. Moore, and M. Jewett, *Issues in the management of stage i testicular seminoma*, International Journal of Radiation Oncology. Biology. Physics, 39 (1997), pp. 156–156.
- [238] P. Warde, M. Gospodarowicz, T. Panzarella, E. Tew-George, M. Milosevic, A. Bayley, C. Catton, J. Sturgeon, M. Moore, and M. Jewett, *Surveillance is an appropriate management strategy in patients with stage i seminoma*, International Journal of Radiation Oncology, Biology, Physics, 54 (2002), p. 61.
- [239] P. Warde, M. O'Malley, M. Jewett, T. Panzarella, D. Hogg, M. Moore, L. Anson-Cartwright, M. Haider, M. Gospodarowicz, and P. Chung, *7108 poster discussion surveillance in stage i testicular cancer—safety of low dose ct scans*, European Journal of Cancer, (2011), pp. S506–S507.
- [240] P. Warde, B. O'Sullivan, T. Panzarella, T. Keane, P. Gullane, D. Payne, F. Liu, M. McLean, J. Waldron, and B. Cummings, *T1/t2 glottic cancer managed by external beam radiotherapy—the influence of pretreatment hemoglobin on local control*, International Journal of Radiation Oncology. Biology. Physics, 36 (1996), pp. 201–201.
- [241] P. Warde, L. Specht, A. Horwich, T. Oliver, T. Panzarella, M. Gospodarowicz, and H. von der Maase, *Prognostic factors for relapse in stage i seminoma managed by surveillance: a pooled analysis*, Journal of clinical oncology, 20 (2002), pp. 4448–4452.
- [242] P. R. Warde, B. O'Sullivan, T. Panzarella, D. G. Payne, F.-F. Liu, J. Waldron, and B. J. Cummings, *T1/t2 glottic cancer managed by external beam radiotherapy—the influence of beam energy on local control*, International Journal of Radiation Oncology, Biology, Physics, 1 (1998), p. 328.
- [243] P. Wheatley-Price, C. Massey, T. Panzarella, F. A. Shepherd, and J. Mikhael, *Resident preparedness in discussing prognosis in patients with advanced lung cancer*, Supportive care in cancer, 18 (2010), pp. 491–497.
- [244] R. K. Wong, D. Letourneau, A. Varma, J. P. Bissonnette, D. Fitzpatrick, D. Grabarz, C. Elder, M. Martin, A. Bezjak, T. Panzarella, et al., *A one-step cone-beam ct-enabled planning-to-treatment model for palliative radiotherapy—from development to implementation*, International Journal of Radiation Oncology* Biology* Physics, 84 (2012), pp. 834–840.
- [245] M. Yap, J. Sappiatzer, M. Tieu, J. Cuartero, T. Panzarella, D. McCready, and A. Fyles, *Abstract p5-14-01: Chest wall bolus in post-mastectomy radiotherapy—is it really necessary?*, Cancer Research, 73 (2013), pp. P5–14.
- [246] M. Yap, M. Tieu, J. Sappiatzer, T. Panzarella, J. Cuartero, D. McCready, and A. Fyles, *Outcomes in patients treated with post-mastectomy chest wall radiotherapy without the routine use of bolus*, Clinical Oncology, 30 (2018), pp. 427–432.

- [247] Q. Yi and T. Panzarella, *Estimating sample size for tests on trends across repeated measurements with missing data based on the interaction term in a mixed model*, *Controlled clinical trials*, 23 (2002), pp. 481–496.
- [248] Q. Yi, T. Panzarella, and P. Corey, *Incorporating the sampling variation of the disease prevalence when calculating the sample size in a study to determine the diagnostic accuracy of a test*, *Controlled clinical trials*, 25 (2004), pp. 417–427.
- [249] D. Zemlickis, M. Lishner, P. Degendorfer, T. Panzarella, B. Burke, S. B. Sutcliffe, and G. Koren, *Maternal and fetal outcome after breast cancer in pregnancy*, *American journal of obstetrics and gynecology*, 166 (1992), pp. 781–787.
- [250] D. Zemlickis, M. Lishner, P. Degendorfer, T. Panzarella, S. Sutcliffe, and G. Koren, *Fetal outcome following in utero exposure to cancer chemotherapy: the toronto study*, *Cancer in Pregnancy: Maternal and Fetal Risks*. Cambridge University Press, Cambridge, (1996), pp. 181–188.
- [251] D. Zemlickis, M. Lishner, P. Degendorfer, T. Panzarella, S. B. Sutcliffe, and G. Koren, *Maternal and fetal outcome after invasive cervical cancer in pregnancy.*, *Journal of clinical oncology*, 9 (1991), pp. 1956–1961.
- [252] ———, *Fetal outcome after in utero exposure to cancer chemotherapy*, *Archives of Internal Medicine*, 152 (1992), pp. 573–576.
- [253] T. Zhong, C. Temple-Oberle, S. Hofer, B. Beber, J. Semple, M. Brown, S. Macadam, P. Lennox, T. Panzarella, C. McCarthy, et al., *The multi centre canadian acellular dermal matrix trial (mccat): study protocol for a randomized controlled trial in implant-based breast reconstruction*, *Trials*, 14 (2013), pp. 1–12.
- [254] T. Zhong, C. Temple-Oberle, S. O. Hofer, B. Beber, J. Semple, M. Brown, S. Macadam, P. Lennox, T. Panzarella, C. McCarthy, et al., *Erratum to: The multi centre canadian acellular dermal matrix trial (mccat): study protocol for a randomized controlled trial in implant-based breast reconstruction*, *Trials*, 17 (2016), pp. 1–1.
- [255] F. S. Zih, N. Wong-Chong, C. Hummel, J. Petronis, T. Panzarella, A. Pollett, A. J. McCart, and C. J. Swallow, *Mucinous tumor of the appendix with limited peritoneal spread: is there a role for expectant observation?*, *Annals of surgical oncology*, 21 (2014), pp. 225–231.